PAD Cases Will Triple by 2050. Here Is What Patients Need to Know Right Now.

A study published in early 2026 in the journal Burns and Trauma delivered a number that should be getting more attention: PAD cases worldwide are projected to increase by 220% before 2050, reaching an estimated 360 million people. That is not a distant threat. For the patients those numbers represent, the disease is progressing right now.

Despite that scale, PAD remains one of the most underdiagnosed and undertreated cardiovascular conditions in the world. Fewer than one in four patients with PAD receives treatment that matches current guidelines. And in a large proportion of those diagnosed, the condition was already advanced by the time anyone looked for it.

Here is what the latest science is telling us, and what it means for patients today.

What PAD Is, and Why It Is More Than a Leg Problem

Peripheral Artery Disease develops when atherosclerosis, the gradual buildup of plaque inside arterial walls, progressively narrows the arteries supplying blood to the legs. Less blood reaches the muscles and tissues. The legs have to work harder with less oxygen. Over time, the gap between what the tissues need and what they receive widens.

What many patients do not realize is that PAD is a whole-body cardiovascular diagnosis. The same process narrowing arteries in your leg is almost certainly affecting arteries elsewhere. PAD patients face a significantly elevated risk of heart attack, stroke, and cardiovascular death, regardless of how severe the leg symptoms currently are.

In fact, many patients have significant PAD before any leg symptoms appear at all.

The Symptoms That Are Easy to Dismiss

PAD is called a silent disease for a reason. For years, the body compensates well enough that symptoms are mild or absent. When they do appear, they are easy to attribute to something else:

• Cramping or aching in the calf, thigh, or hip during walking that eases with rest
• One foot that feels colder than the other, or looks paler
• Cuts or sores on the feet or lower legs that take unusually long to heal
• Shiny, thin skin on the lower leg
• A weak or absent pulse in the foot

If any of these are familiar, the right first step is a simple, non-invasive test called an ankle-brachial index (ABI). It takes about 15 minutes and can detect arterial disease before it progresses to a dangerous stage.

What Changed in 2026: New Findings and Updated Guidelines

Two significant developments in early 2026 are directly relevant to PAD patients and those caring for them.

First, the American Heart Association released updated cholesterol guidelines in 2026. For PAD patients, this matters because plaque buildup in arteries is directly driven by LDL cholesterol levels, and the new targets are more aggressive than previous recommendations. If your LDL management has not been reviewed recently, that conversation with your doctor is overdue.

Second, a major clinical trial published in JAMA in January 2026 found that metformin, a widely used diabetes medication, does not improve walking distance in PAD patients without diabetes. This is useful information for patients who may have been prescribed it off-label for that purpose. Researchers are now actively studying alternative approaches, including cocoa flavanols and nicotinamide riboside, which have shown early promise in improving walking function in PAD.

When PAD Becomes an Emergency

For most patients, PAD is manageable with medication, lifestyle changes, and supervised exercise. The critical window is before the disease advances to its most severe stage, called Chronic Limb-Threatening Ischemia (CLTI), where blood flow has deteriorated so severely that tissue begins to break down.

At that point, the conversations change. The options become fewer. The stakes become significantly higher.

Caught early, PAD is a disease you manage. Caught late, it is a disease that manages you.